Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020199650 - APPLICATION OF EDARAVONE IN TREATMENT OR PREVENTION OF NON-ALCOHOLIC STEATOHEPATITIS

Publication Number WO/2020/199650
Publication Date 08.10.2020
International Application No. PCT/CN2019/125557
International Filing Date 16.12.2019
IPC
A61K 31/4152 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
4152having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
06Antihyperlipidemics
A61P 3/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 9/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
08Vasodilators for multiple indications
Applicants
  • 苏州澳宗生物科技有限公司 SUZHOU AUZONE BIOLOGICAL TECHNOLOGY CO., LTD [CN]/[CN]
Inventors
  • 丁海峰 DING, Haifeng
  • 周意 ZHOU, Yi
Agents
  • 中原信达知识产权代理有限责任公司 CHINA SINDA INTELLECTUAL PROPERTY LIMITED
Priority Data
201910249289.329.03.2019CN
201910537638.120.06.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) APPLICATION OF EDARAVONE IN TREATMENT OR PREVENTION OF NON-ALCOHOLIC STEATOHEPATITIS
(FR) UTILISATION D'ÉDARAVONE DANS LE TRAITEMENT OU LA PRÉVENTION DE LA STÉATOHÉPATITE NON ALCOOLIQUE
(ZH) 依达拉奉在非酒精性脂肪肝炎治疗或预防中的应用
Abstract
(EN)
An application of edaravone in the treatment or prevention of non-alcoholic steatohepatitis. Specifically, an application of edaravone or a pharmaceutically acceptable salt or an analogue or a derivative thereof in the preparation of a drug for the treatment or prevention of non-alcoholic fatty liver disease (NAFLD), particularly non-alcoholic steatohepatitis (NASH).
(FR)
L'invention concerne une utilisation de l'édaravone dans le traitement ou la prévention de la stéatohépatite non alcoolique. Spécifiquement, l'invention concerne une utilisation d'édaravone ou d'un sel pharmaceutiquement acceptable ou d'un analogue ou d'un dérivé de celle-ci dans la préparation d'un médicament pour le traitement ou la prévention de la stéatose hépatique non alcoolique (NAFLD), en particulier la stéatohépatite non alcoolique (NASH).
(ZH)
依达拉奉在非酒精性脂肪肝炎治疗或预防中的应用。具体而言,依达拉奉或其药学可接受的盐或类似物或衍生物在制备用于治疗或预防非酒精性脂肪肝病(NAFLD),尤其是非酒精性脂肪性肝炎(NASH)的药物中的应用。
Latest bibliographic data on file with the International Bureau